ABT-737, an inhibitor of Bcl-2 family proteins, is a potent inducer of apoptosis in multiple myeloma cells-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

ABT-737, an inhibitor of Bcl-2 family proteins, is a potent inducer of apoptosis in multiple myeloma cells

Published:2007-04-26 Issue:7 Volume:21 Page:1549-1560
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Kline M P,Rajkumar S V,Timm M M,Kimlinger T K,Haug J L,Lust J A,Greipp P R,Kumar S

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

http://www.nature.com/articles/2404719.pdf

Reference40 articles.

1. Kyle RA, Rajkumar SV . Multiple myeloma. N Engl J Med 2004; 351: 1860–1873.

2. Witzig TE, Dhodapkar MV, Kyle RA, Greipp PR . Quantitation of circulating peripheral blood plasma cells and their relationship to disease activity in patients with multiple myeloma. Cancer 1993; 72: 108–113.

3. Rajkumar SV, Kyle RA . Multiple myeloma: diagnosis and treatment. Mayo Clin Proc 2005; 80: 1371–1382.

4. Greipp PR, Witzig TE, Gonchoroff NJ, Habermann TM, Katzmann JA, O'Fallon WM et al. Immunofluorescence labeling indices in myeloma and related monoclonal gammopathies. Mayo Clin Proc 1987; 62: 969–977.

5. Witzig TE, Timm M, Larson D, Therneau T, Greipp PR . Measurement of apoptosis and proliferation of bone marrow plasma cells in patients with plasma cell proliferative disorders. Br J Haematol 1999; 104: 131–137.

Cited by 136 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Biomarker-directed therapy in multiple myeloma;Current Opinion in Oncology;2024-08-23

2. Mitochondria of T Lymphocytes Promote Anti-Pulmonary Tumor Immune Response;World Journal of Oncology;2024-06

3. Clinical pharmacokinetics and pharmacodynamics of venetoclax, a selective B‐cell lymphoma‐2 inhibitor;Clinical and Translational Science;2024-05

4. Rational Formulation of targeted ABT-737 nanoparticles by self-assembled polypeptides and designed peptides;Heliyon;2024-02

5. Bcl-2 inhibition in the treatment of hematologic malignancies;Frontiers in Hematology;2023-12-04

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3